Update on Pediatric Opsoclonus Myoclonus Syndrome

Abstract

Opsoclonus myoclonus syndrome (dancing eye syndrome) is a rare paraneoplastic syndrome characterized by opsoclonus, myoclonus, and ataxia, usually accompanied by behavioral abnormalities. In adults, opsoclonus myoclonus syndrome has been reported in association with different types of cancer; whereas in children, the syndrome may be associated with neuroblastic tumors. Although a direct proof is lacking, the syndrome is assumed to be of autoimmune origin. The treatment is corticosteroid based with the addition of other immunosuppressive or immunomodulating drugs if intensification seems necessary. Because of the rarity of the disease, international collaborations as well on research as on therapeutic strategies are urgently needed. A European consortium just started a trial for this rare condition.

Keywords

opsoclonus myoclonus syndrome - dancing eye syndrome - neuroblastoma

• References

• 1 Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962; 25: 271-276
• 2 Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28 (4) 284-288
• 3 Rudnick E, Khakoo Y, Antunes NL , et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36 (6) 612-622
• 4 Plantaz D, Michon J, Valteau-Couanet D , et al; Study of the French Society of Pediatric Oncologists. [Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival]. Arch Pediatr 2000; 7 (6) 621-628
• 5 Roberts KB. Cerebellar ataxia and “occult neuroblastoma” without opsoclonus. Pediatrics 1975; 56: 464-465
• 6 Herman TE, Siegel MJ. Ataxia without opsoclonus: right lumbar sympathetic trunk neuroblastoma. Clin Pediatr (Phila) 2009; 48: 336-340
• 7 Wolff M, Schoning M, Niemann G, Krageloh-Mann I. Late detection of neuroblastoma in a patient with prolonged cerebellar ataxia without opsoclonus. Neuropediatrics 2001; 32: 101-103
• 8 Mitchell WG, Davalos-Gonzalez Y, Brumm VL , et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109 (1) 86-98
• 9 Matthay KK, Blaes F, Hero B , et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005; 228 (1-2) 275-282
• 10 Bataller L, Graus F, Saiz A, Vilchez JJ ; Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124 (Pt 2) 437-443
• 11 Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009; 24 (12) 1715-1724
• 12 Titulaer MJ, Soffietti R, Dalmau J , et al; European Federation of Neurological Societies. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18 (1) 19-e3
• 13 Fitzpatrick AS, Gray OM, McConville J, McDonnell GV. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology 2008; 70 (15) 1292-1293
• 14 Wilfong AA, Parke JT, McCrary III JA. Opsoclonus-myoclonus with Beckwith-Wiedemann syndrome and hepatoblastoma. Pediatr Neurol 1992; 8 (1) 77-79
• 15 Huber BM, Strozzi S, Steinlin M, Aebi C, Fluri S. Mycoplasma pneumoniae associated opsoclonus-myoclonus syndrome in three cases. Eur J Pediatr 2010; 169 (4) 441-445
• 16 Ertekin V, Tan H. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection. Pediatr Neurol 2010; 42 (6) 441-442
• 17 Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 2010; 14 (2) 156-161
• 18 Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1992; 15 (3) 186-228
• 19 Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005; 22 (1) 8-19
• 20 Pohl KR, Pritchard J, Wilson J. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr 1996; 155 (3) 237-244
• 21 Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child 2012; 97 (5) 461-463
• 22 Mutch LS, Johnston DL. Late presentation of opsoclonus-myoclonus-ataxia syndrome in a child with stage 4S neuroblastoma. J Pediatr Hematol Oncol 2005; 27 (6) 341-343
• 23 Jamroz E, Głuszkiewicz E, Madziara W, Kiełtyka A. [Opsoclonus-myoclonus syndrome in a 2.  year old boy with prenatally diagnosed retroperitoneal tumour]. Med Wieku Rozwoj 2011; 15 (2) 151-156
• 24 Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971; 27 (2) 374-378
• 25 D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1 (7708) 1046-1049
• 26 Evans AE, Baum E, Chard R. Do infants with stage IV-S neuroblastoma need treatment?. Arch Dis Child 1981; 56 (4) 271-274
• 27 Hero B, Simon T, Spitz R , et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26 (9) 1504-1510
• 28 Krug P, Schleiermacher G, Michon J , et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14 (5) 400-409
• 29 Hiyama E, Yokoyama T, Ichikawa T , et al. Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer 1994; 74 (6) 1821-1826
• 30 Gambini C, Conte M, Bernini G , et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003; 442 (6) 555-562
• 31 Cooper R, Khakoo Y, Matthay KK , et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001; 36 (6) 623-629
• 32 Hero B, Radolska S, Gathof BS. Opsomyoclonus syndrome in infancy with or without neuroblastoma is associated with HLA DRB1*01 (abstract). Ped Blood Cancer 2005; 45
• 33 Krasenbrink I, Fühlhuber V, Juhasz-Boess I , et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatrics 2007; 38 (3) 114-116
• 34 Oguro K, Kobayashi J, Aiba H, Hojo H. Opsoclonus-myoclonus syndrome with abnormal single photon emission computed tomography imaging. Pediatr Neurol 1997; 16 (4) 334-336
• 35 Hayward K, Jeremy RJ, Jenkins S , et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001; 139 (4) 552-559
• 36 Luque FA, Furneaux HM, Ferziger R , et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29 (3) 241-251
• 37 Dalmau J, Graus F, Cheung NK , et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 1995; 75 (1) 99-109
• 38 Antunes NL, Khakoo Y, Matthay KK , et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22 (4) 315-320
• 39 Fisher PG, Wechsler DS, Singer HS. Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol 1994; 10 (4) 309-312
• 40 Connolly AM, Pestronk A, Mehta S, Pranzatelli III MR, Noetzel MJ. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997; 130 (6) 878-884
• 41 Noetzel MJ, Cawley LP, James VL, Minard BJ, Agrawal HC. Anti-neurofilament protein antibodies in opsoclonus-myoclonus. J Neuroimmunol 1987; 15 (2) 137-145
• 42 Blaes F, Fühlhuber V, Korfei M , et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58 (2) 313-317
• 43 Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53 (3) 347-353
• 44 Korfei M, Fühlhuber V, Schmidt-Wöll T, Kaps M, Preissner KT, Blaes F. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol 2005; 170 (1-2) 150-157
• 45 Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord 2004; 19 (7) 770-777
• 46 Pranzatelli MR, Tate ED, Travelstead AL, Colliver JA. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol 2010; 30 (1) 106-113
• 47 Pranzatelli MR, Tate ED, McGee NR , et al. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflammation 2013; 10: 10
• 48 Fühlhuber V, Bick S, Kirsten A , et al. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 2009; 210 (1-2) 87-91
• 49 Raffaghello L, Fuhlhuber V, Bianchi G , et al. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity. J Leukoc Biol 2013; 94 (1) 183-191
• 50 Raffaghello L, Conte M, De Grandis E, Pistoia V. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. Eur J Paediatr Neurol 2009; 13 (3) 219-223
• 51 Posner JB. Paraneoplastic opsoclonus/myoclonus: B cells, T cells, both, or neither?. Neurology 2004; 62 (9) 1466-1467
• 52 Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr 2007; 166 (4) 359-363
• 53 De Grandis E, Parodi S, Conte M , et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009; 40 (3) 103-111
• 54 Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML, van Noesel MM, Hakvoort-Cammel FG, van den Heuvel-Eibrink MM. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer 2009; 53 (6) 1048-1053
• 55 Mitchell WG, Brumm VL, Azen CG, Patterson KE, Aller SK, Rodriguez J. Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia. Pediatrics 2005; 116 (4) 901-907
• 56 Turkel SB, Brumm VL, Mitchell WG, Tavare CJ. Mood and behavioral dysfunction with opsoclonus-myoclonus ataxia. J Neuropsychiatry Clin Neurosci 2006; 18 (2) 239-241
• 57 Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics 2011; 128 (2) e388-e394
• 58 Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Curr Opin Pediatr 2010; 22 (6) 745-750
• 59 Timmann D. [Contribution of the cerebellum to cognition]. Fortschr Neurol Psychiatr 2012; 80 (1) 44-52
• 60 Ki Pang K, Lynch BJ, Osborne JP, Pike MG. Dancing Eye Syndrome associated with spontaneous recovery and normal neurodevelopment. Eur J Paediatr Neurol 2010; 14 (2) 178-181
• 61 Emir S, Akyüz C, Büyükpamukçu M. Correspondence: treatment of the neuroblastoma-associated opsoclonus-myoclonus-ataxia (OMA) syndrome with high-dose methylprednisolone. Med Pediatr Oncol 2003; 40 (2) 139
• 62 Rostásy K, Wilken B, Baumann M , et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatrics 2006; 37 (5) 291-295
• 63 Borgna-Pignatti C, Balter R, Marradi P, Colamaria V. Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus. J Pediatr 1996; 129 (1) 179-180
• 64 Petruzzi MJ, de Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 1995; 127 (2) 328-329
• 65 Pless M, Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996; 46 (2) 583-584
• 66 Veneselli E, Conte M, Biancheri R, Acquaviva A, De Bernardi B. Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol 1998; 30 (1) 15-17
• 67 Yiu VW, Kovithavongs T, McGonigle LF, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 2001; 24 (1) 72-74
• 68 Pranzatelli MR, Tate ED, Travelstead AL , et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24 (3) 316-322
• 69 Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005; 115 (1) e115-e119
• 70 Bell J, Moran C, Blatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 2008; 50 (2) 370-371
• 71 Burke MJ, Cohn SL. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr Blood Cancer 2008; 50 (3) 679-680
• 72 Pranzatelli MR, Tate ED, Travelstead AL , et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28 (9) 585-593
• 73 Pranzatelli MR, Tate ED, Verhulst SJ , et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2010; 32 (5) e167-e172
• 74 Ertle F, Behnisch W, Al Mulla NA , et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008; 50 (3) 683-687
• 75 Tam C, Seymour JF, Brown M , et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 2005; 90 (5) 700-702
• 76 Quartier P, Tournilhac O, Archimbaud C , et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003; 36 (3) e47-e49
• 77 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9 (4) 425-437